Today's Rundown What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling Gossamer's Dupont jumps to Atara Biotherapeutics Sanofi nabs speedy review of sutimlimab, aiming for a November approval [Sponsored] The COVID-19 crisis: Five ways pharmaceutical leaders can rise to the challenge Boehringer nabs Northern Biologics preclinical assets, pens eye disease drug pact J&J taps Lava to develop anti-cancer gamma-delta T-cell engagers How an old antipsychotic might treat brain and spinal cord injuries NYU study flags false negatives from Abbott's portable coronavirus test, while FDA lists concerns FiercePharmaAsia—Gilead's remdesivir licensing; Legend's $100M IPO; Takeda's blockbuster hopefuls Chutes & Ladders—GSK vaccines vet Slaoui to lead project 'Warp Speed' Featured Story | | | Friday, May 15, 2020 After pulling the plug on its first IPO attempt, ADC Therapeutics tried its luck during a pandemic. That gamble has paid off—the cancer drug developer reeled in $233 million in its Wall Street debut, outraising its original goal by more than $80 million. The proceeds will push the company’s lead programs through pivotal phase 2 studies. |
|
|---|
|
Top Stories Thursday, May 14, 2020 Gossamer Bio revealed this week that its chief medical officer, Jakob Dupont, M.D., would be departing to “pursue oncology opportunities closer to his family.” Two days later, we know where he’s landed: Atara Biotherapeutics, a South San Francisco biotech working on off-the-shelf T-cell therapies. Friday, May 15, 2020 After posting positive late-stage results for its rare blood disease drug, Sanofi has been handed a priority review from the FDA for sutimlimab. Monday, May 11, 2020 Amid the COVID-19 crisis, Takeda leaders share five ways to adjust to protect people’s families, colleagues and community, while maintaining a commitment to the people who need Takeda’s medicines. Friday, May 15, 2020 Boehringer Ingelheim is boosting its early-stage bets while also inking a new deal to work on a therapy against a leading cause of blindness. Friday, May 15, 2020 Johnson & Johnson has formed a collaboration with Lava Therapeutics to develop gamma-delta T-cell engagers. The agreement moves J&J into an emerging corner of the immuno-oncology sector that has attracted the interest of companies including Pfizer Ventures and Takeda. Thursday, May 14, 2020 An international team led by scientists at Aston University may have found a new use for the old antipsychotic trifluoperazine—reducing dangerous brain swelling after traumatic injuries. The drug works by changing the behavior of tiny protein pores in our cells, the researchers say. Thursday, May 14, 2020 A new study measuring the performance of Abbott’s rapid, point-of-care coronavirus test found the device could miss nearly half of positive cases, depending on how the samples were handled and fed into the machine. Conducted by researchers at NYU Langone Health, the study was pre-published on bioRxiv, and has not yet been peer-reviewed. Friday, May 15, 2020 Gilead is licensing COVID-19 therapy remdesivir to five generics makers to primarily supply low-income countries. Johnson & Johnson's CAR-T partner Legend Biotech is looking to raise $100 million in a Nasdaq IPO. Takeda plots 12 new drug launches by 2024 with aggregate peak sales of $10 billion. And more. Friday, May 15, 2020 Trum administration taps Slaoui for "Warp Speed" project; Regev joins Roche; Caribou names Thomas as clinical lead. | | Experts in our field; with 20+ years’ experience in Viral Vector & plasmid DNA (R&D, High Quality and GMP) manufacture for pre-clinical, clinical & commercial supply. Take a virtual tour of our facilities & find out more about our expansion project. |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|---|
|
Resources Presented by: Optum The immediacy of EHR data availability can be significantly impactful, particularly as the health care system works to address COVID-19. Download this whitepaper to learn more. Sponsored by: Patheon, by Thermo Fisher Scientific Continuous Manufacturing vs. Batch for Oral Solid Dose Sponsored by: Cenduit, LLC Download this case study to read about how Cenduit navigated these challenges, and successfully supports the trial sponsor to execute the umbrella trial with agility. Sponsored by: Patheon, by Thermo Fisher Scientific Download this whitepaper to learn more about the importance of an integrated approach to formulation. Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Clarify Health Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. Sponsored by: Recro Gainesville Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project. Sponsored by: AMRI In this webinar, the featured speaker will explore the key advances and critical hurdles for translating these emerging molecular biology technologies into real-world applications and commercial processes. Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug. Download the whitepaper. Sponsored by: Blue Latitude Health Report: Think you’re patient-centric? Think again. Find out how patients really feel about patient-centricity. Learn what they would like to experience along with tools and tips for maximising patient engagement across the product life cycle¬ – from clinical trials to service design and creative campaigns. Sponsored by: Lonza This whitepaper summarises approaches for modulating antibody effector functions and pharmacokinetics, and provides examples of antibodies in clinical studies. Sponsored by: BBK Worldwide Leverage strategic solutions to respond to immediate challenges to patient and site engagement from COVID-19, and learn to maximize the FDA guidance on the conduct of clinical trials during a pandemic. Sponsored by: Outer Edge Technology To survive in these challenging conditions, companies need to promptly address business continuity issues - especially the remote delivery of data and voice solutions. See how Outer Edge can help. Sponsored by: Patheon, by Thermo Fisher Scientific Poorly soluble molecules hindering your workflow? Sponsored by: eClinical Solutions Key findings from the 2019 Life Sciences Data & Analytics Survey conducted by the Tufts Center for the Study of Drug Development will be unveiled during this live webinar led by industry expert and study lead, Ken Getz, Director of Sponsored Programs and Associate Professor. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Medical Affairs Strategic Summit (MASS) East April 14-16, 2020 | New Brunswick, NJ 8-week Online Courses in Life Sciences Law and Compliance Virtual Course | May 31st, 2020 PEGS Virtual Interactive Summit Virtual Event | June 2-26, 2020 European Healthcare Compliance Certificate Program June 2-5, 2020 | Paris, France BIO 2020 Now Fully Virtual: Announcing BIO Digital June 8-11, 2020 | Virtual Event Virtual Series: Clinical Trials June 22-24, 2020 | Free Virtual Event Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training is in session. | Take your new medicine development skills to the next level. | 